The observed or predicted behaviour of a system used for the basis of simulation. Models allow the understanding of complex systems and prediction of their behaviour. A model may give incorrect descriptions and predications for situations outside the realm of its intended use.
HIV and AIDS is a global pandemic that has claimed many millions of lives since the disease was first described in 1981. Today, it is estimated that over 33 million people are living with HIV (see the UNAIDS 2008 report on the global AIDS epidemic), despite exhaustive efforts to control the spread of the infection. Although improved education programmes, barrier techniques and anti retroviral therapies help to decrease the virus transmis sion and mortality rates, a large number of HIVinfected indiv iduals cannot obtain antiretroviral drugs, which are customized, expensive and often inaccessible. It is widely agreed that a vaccine that prevents or controls HIV infec tion would help to control this devastating epidemic. However, such a vaccine remains elusive.
In light of the failure of a recent clinical trial of a leading Merck & Co. HIV vaccine (the STEP trial), re evaluation of the use of nonhuman primate models for HIV vaccine preclinical development is important [1] [2] [3] . The relevance of the rhesus macaque model to human HIV vaccine development has been recently reviewed in articles that focused for the most part on the similari ties between rhesus macaques and humans [4] [5] [6] [7] . However, although we agree that the use of animal models for the study of HIV and AIDS is crucial for understanding viral immunobiology and for the rational design of vaccines and therapies, we also need to consider that there are important differences between these two species that should not be ignored.
Historically, the use of animal models for the study of human disease has had obvious advantages: fundamental properties of the disease can be inves tigated more invasively and thoroughly, while drug and vaccine toxicity and efficacy studies can provide proofofconcept for advancing trials into human subjects, limiting the risk, time and cost of clinical trials 4 . Preclinical data generated in animal models serve collectively as a gatekeeper for the progression of candidate vaccines to evaluation in a clinical setting. Researchers have made a considerable effort to gen erate animal models for human diseases, even when this endeavour is not straightforward, as is the case for HIV and AIDS 4 . The major limitation surrounding HIV study in animal models is that the virus does not rep licate in most animal species tested, including rodents 8 and nonhuman primates 4 (the rare exceptions being gibbon apes and chimpanzees; however, in these ani mals HIV1 infection is typically not associated with clinical diseases and haematological abnormalities 2, 4 ). Although chimpanzees are the closest species in evolu tionary terms to humans, they are endangered, they are costly to maintain and their use can be of ethical concern. Thus, the focus has shifted to viral surrogates of HIV, simian immunodeficiency viruses (SIVs), for which infection in natural nonhuman primate hosts, such as sooty mangabeys and African green monkeys, is generally nonpathogenic 9, 10 , but experimental
Gatekeeper
User-defined criteria with dynamic, technical qualifications and standards deemed by the scientific and medical communities as important for safety and efficacy for vaccine advancement in humans. Data that achieve gatekeeper status must exceed these defined criteria.
Heterologous prime-boost immunization protocols
The use of different formulations to initiate and to boost the immune response. This approach often elicits T cell responses of greater breadth, magnitude or quality than homologous immunization, in which the same antigen formulation is repeatedly administered.
Viral set point
The time at which plasma viraemia settles to a stable level (within approximately 3-6 months of the onset of HIV infection). Viral set point is strongly predictive of both how quickly HIV infection will progress and the risk of HIV transmission.
infection of nonnatural hosts, such as Asian monkey species, including rhesus macaques (Macaca mulatta), results in the development of disease similar to that described in patients with AIDS (simian AIDS) 11 . Studies carried out in the late 1980s and early 1990s were greeted with excitement when recombinant live vac cines 12 and DNA vaccines [13] [14] [15] elicited measurable CD8 + cytotoxic T lymphocyte (CTl) responses in both rhesus macaques 16 and humans, and recombinant protein and peptidebased vaccines induced measurable levels of neutralizing antibodies [16] [17] [18] [19] . However, Phase III clinical studies showed that recombinant HIV envelope (Env) expressing vaccines could not stimulate antibodies that had a broad enough spectrum to protect against viral transmission, even against closely matched viruses 20, 21 . It soon became evident that similar vaccines capable of elic iting neutralizing antibodies against chimeric HIV Env expressing SIVs (SHIVs) in nonhuman primates [22] [23] [24] [25] could not protect rhesus macaques against subsequent challenge with divergent SHIVs, and SIVmac was resist ant to neutralization. [26] [27] [28] [29] . based on these findings, the hope for a quick solution to the HIV vaccine problem through the induction of neutralizing antibody responses faded dramatically.
As a result, many researchers in the field refocused their studies to develop immunization approaches based on exploiting antiviral T cell responses. Preliminary evi dence in nonhuman primates supported the notion that such a vaccineengineered response might limit, at least partially, challenges with SIV strains that were distinct to the vaccine strain. This shift in thinking was accompanied by a focus on the development of potent vector systems for inducing HIVspecific CTl responses. of note, the goal of these vaccines was not to induce sterilizing immunity, but rather to decrease the rate of disease progression after infection by lowering virus load. This secondgeneration vaccine strategy included the study of advanced recom binant viral vectors such as adenovirus vectors express ing HIV and/or SIV proteins, and could stimulate strong CTl responses alone as well as in heterologous primeboost immunization protocols in primates, which have been standard for most of the past decade. Preclinical studies of these adenovirusbased vaccines in rhesus macaques were promising and induced protection (defined as lower viral loads or greater survival after challenge than in non vaccinated control animals) against SHIV challenges 22, 25 , thus generating considerable optimism. However, con cerns were raised regarding the rapid pathogenesis and unusual coreceptor usage by specific SHIVs or the complete lack of pathogenesis of other SHIVs. Subsequent studies showed that this vaccine approach offered little protection against pathogenic SIV challenge when administered to outbred genetic haplotypes 26 . Despite the ensuing debate regarding the relevance of various SIV and SHIV challenge models to human HIV infection, adenovirus serotype 5 (Ad5) studies advanced into clinical trials for efficacy based on the assumptions that protection (defined as lower peak viral loads and viral set point with delayed progression to disease) in rhesus macaques against pathogenic SHIV challenge equates to protection in humans, and nonprotection in rhesus macaques equates to nonprotection in humans. The STEP Phase IIb clinical trial evaluated the efficacy of a replicationincompetent Ad5based vaccine encod ing HIV Gag, Pol and Nef in stratified Ad5seropositive individuals living in the Americas and Australia 30 . However, the vaccine showed a complete lack of efficacy in preventing either infection or disease progression. The vaccine even seemed to increase HIV transmission rates in those Ad5seropositive vaccine recipients that had high Ad5specific antibody titres 3, 30 , a result that was not anticipated from studies in rhesus macaques.
The rhesus macaque model has so far been used extensively in the development of HIV vaccines as a sur rogate for studying human HIV infection 5, 6 . However, the extent of our knowledge about rhesus macaque mod els is questionable. This Review examines what we can learn from previous studies of human disease in rhesus macaques and how we can best use the nonhuman pri mate model in the context of preclinical development for human HIV vaccine trials.
Rhesus macaques and the study of human disease Rhesus macaques are old world monkeys that diverged approximately 25 million years ago from the lineage that led to both chimpanzees and humans. owing to their relative genetic and physiological similarities to humans and their extensive availability, rhesus macaques are the most widely used nonhuman primates in basic and applied research 31 . However, despite their evolutionary links with humans, there are significant differences that may be relevant to the study of human disease (TABLE 1) . For example, the composition of the bacterial flora in the gut 32 differs between rhesus macaques and humans and may have a significant influence on mucosal immunology patterns, which are important when considering vaccines delivered to mucosal sites, such as live attenuated vectors that are administered orally. Furthermore, differences in the biology at subcutaneous vaccination sites may affect vaccinespecific immunity: the distribution and compo sition of muscle fibres, the prevalence of interstitial and intratissue fat and tissue vascularization can directly influence vaccine distribution, diffusion of the formula tion, its rate of clearance and the types of host cell encoun tered. Differences in these variables could contribute to the difference in immune responses induced by various vaccines between rhesus macaques and humans.
Although rhesus macaques have proved to be invalu able in the study of some human diseases, they are an imperfect system for the study of others. For example, the human teratogen thalidomide (Thalomid; Celgene) does not induce birth defects when administered orally to pregnant rhesus macaques 33 . In addition, rhesus macaques have been suggested as a potential animal model for asthma owing to their development of a humanlike asthma phenotype and their responsive ness to some human antiasthma drugs; however, the experimental antiasthma drugs developed in the rhe sus macaque asthma model were ineffective in treating the human disease [34] [35] [36] . As discussed elsewhere 36 , "the problem with animal models of asthma is that it is pos sible to obtain evidence for almost any theory, simply by choosing the appropriate conditions. The only way to be sure that a particular model is predictive for clini cal asthma is to know the answer in advance and adjust the conditions accordingly to ensure the appropriate results. " Furthermore, diseaserelated genes are differ ent in the two species; for example the genes associated with phenylketonuria and cystic fibrosis in humans are not related to disease in rhesus macaques. Indeed there are fewer cancerrelated genes and more immune system genes, including MHC copy numbers 37 and immuno globulin λlike gene clusters, in rhesus macaques than in humans 38 (TABLE 1) . So, it is important to remain cautious when interpreting data generated in the rhesus macaque models in the absence of known human disease mechanisms.
Human vaccine research has been affected by incor rect scientific assumptions about the relative importance of a particular primate infection model. For example, studies using rhesus macaques as a model for poliovirus by Simon Flexner in the early 1900s impeded the devel opment of a poliovirus vaccine 39 . Flexner was the labo ratory director of the Rockefeller Institute for Medical Research in New York from 1863 to 1946 and a leading expert in pathology and bacteriology. He was considered to be the most prominent poliovirus researcher during this period and renowned for his research on cerebro spinal meningitis, poliovirus and infantile paralysis. both his choice of the rhesus macaque model and his method of inducing the disease in these animals had unforeseen consequences 40 . Flexner injected poliovirus directly into the brain or spine of rhesus macaques, as well as intra nasally, and observed neurovirulent disease and paraly sis similar or identical to symptoms of human polio. The virus replicated at high levels in the nervous system, but no blood stage of viral replication was detected. Flexner and colleagues therefore concluded that the mechanism for poliovirus transmission in humans was via a direct route to the brain, probably by infection of the nasal mucosa. This interpretation influenced both public health strategies and vaccine approaches against polio. However, at the time it was unknown that the rhesus macaque, unlike the cynomolgus macaque (Macaca fascicularis), is one of the rare monkeys in which polio virus does not replicate in the digestive tract and sub sequently does not cause an orally acquired infection. Unfortunately, Flexner's conclusions that vaccines may be impossible to develop owing to the absence of a blood replication stage for poliovirus and that vaccine candi dates should be grown only in neural cell lines, ideas that were widely embraced by the poliovirus research field, delayed the development of an effective poliovirus vaccine by as many as 40 years. Thus, this interpreta tion from the rhesus macaque model system shows that scientific assumptions of the importance of a particular primate infection model, based on the manifestation of similar disease symptoms and in the absence of known human correlates, may be ultimately misleading 41 . owing to nearly 25 million years of evolution, the abundance and degree of polymorphism of MHC genes have diverged significantly between humans and rhe sus macaques 37, 38 (TABLE 1) . Currently, we do not fully appreciate the contribution of rhesus macaque MHC molecules to the induction of immunity, especially as an increased ability to recognize and respond to vaccine antigen may directly affect the quality of the immuno logical memory [42] [43] [44] . For example the presence of MHC haplotypes that correlate with viral control seems to affect the outcome of HIV and SIV infection 45 . The increased expression of MHC genes in rhesus macaques might boost their ability to spontaneously control virus as the rhesus macaque MHC class I alleles Mamub08 and Mamub03, and Mamub17 are associated with control of over 50% and 20% of cases of SIV 46, 47 , respectively, whereas most (>98%) humans expressing HlAb57 and HlAb27 (HlA allele haplotypes linked with virus control in some people) do not control HIV infection (M. Connors, personal communication). Therefore, it is probable that speciesspecific differences in immune gene expression have an important role in disease outcome and therefore the study of vaccines.
The fact that vaccineinduced T cell immunity can be more readily achieved in rhesus macaques than in humans might also be related to the anecdotal observa tion that T cell responses in rhesus macaques seem to be larger and broader than those induced in humans by identical vaccine preparations. Such differences may be advantageous when carrying out immunoassays that would otherwise fall below the limit of detection, but may also cause undue optimism when evaluating a candidate T cell vaccine in rhesus macaques. Historically, this has been the case in most clinical trials assessing vaccine specific T cellmediated responses (TABLE 2) . For exam ple, HIV DNA vaccines in humans induced response rates that were significantly lower than those observed in rhesus macaques: Gagexpressing Ad5based vac cines induced responses to only a few epitopes in humans whereas responses to more epitopes were induced by the same vaccines in rhesus macaques. with regard to the use of animal models for vaccine development, it could be said that 'mice lie and monkeys exaggerate' . Fewer HLA-DRB genes than in rhesus macaques *The rhesus macaque diet in the wild is mainly herbivorous and less atherogenic than the human diet. These differences might influence the immunology of the gut mucosa in the two species. ‡
Percentage of individuals expressing the haplotype or haplotypes that control the virus.
An 'exaggerated' immune response was observed in mon keys during the study of specific topical virustatic micro bicides. These compounds, which are topically applied inside the vagina or rectum, are designed to provide an additional limitation to the transmission of sexual infec tions beyond vaccination 48 . Promising results from pre clinical challenge studies in rhesus macaques supported the clinical development of such compounds but have correlated poorly with the outcome of clinical trials, for example those of nonoxynol9 and cellulose sulphate 52 (TABLE 2) . In fact, reminiscent of the results of the STEP trial, use of these compounds increased the incidence of viral transmission in the clinic, a result never observed in the preclinical macaque model 49, 50, [52] [53] [54] [55] . SIV biology in a nonnatural host may account for some of the discrepancies observed between rhesus macaque and clinical data. Sexual transmission of SIV is thought to be the predominant avenue in natural hosts, but it has been difficult to show this in experimentally infected rhesus macaques; a single report has described the potential sexual transmission from female to male pigtailed macaques (Macaca nemestrina) of SIVmne 56 . Sexual transmission of SIV in rhesus macaques does not occur despite detection of virus in all levels of the male reproductive tract 57 . This is unusual as SIV is known to infect stratified squamous cells in the mucosal epithe lium of the foreskin and glans of the penis 57 , in which CD4 + langerhans cells are abundant 58 . Risk behaviour is signif icantly different between the two species and coitus in rhesus macaques is very brief, whereas human sexual activity can be longer in duration, higher in frequency and more irritating to the genital mucosa, all of which may enhance the transmission of HIV 59, 60 . Furthermore, marked differences in the kinetics of HIV and SIV replica tion may also account for the differences between the data obtained from the rhesus macaque model and human dis ease [61] [62] [63] [64] [65] [66] [67] (fIG. 1) . The importance of circumcision in HIV transmission further complicates the rhesus macaque challenge models. Thus, when using experimental SIV infection in nonnatural rhesus macaque hosts as a model for studying HIV vaccines and disease in humans, we must also acknowledge the key differences in viral biol ogy that may contribute to disease outcomes in vaccine settings. Given the apparent failure of rhesus macaques to emulate human disease patterns, we next review how the data generated in rhesus macaques have overwhelmingly attained gatekeeper status in HIV vaccine studies.
Gatekeepers for HIV clinical trials
Traditionally, preference for the use of nonhuman pri mate models for studying human disease was based on several characteristics, including the recapitulation of human disease or its pathology, genetic similarities and the availability of the animal for such studies. In the case of HIV, there was an initial reluctance to give the data generated in nonhuman primate models any gatekeeper status in the vaccine testing pathway out of concern that potentially effective vaccine candidates might thereby be SIV HIV missed 6 ; particular concerns were the recapitulation of HIV disease in nonhuman primates and the stringency of experimental challenge models. However, nonhuman primate models have had an integral role in HIV research and vaccine testing and, owing to the identification of immunogens with increased immunogenicity and the screening out of lowefficacy candidates, they have now become a much higher priority component of preclini cal HIV vaccine tests 6 . This is especially significant when considering the cost and regulatory requirements associ ated with the manufacture of vaccines for clinical trials.
one of the first nonhuman primate models used to study HIV pathogenesis and vaccines was chimp anzees 68 . based on the finding that antibodies from the sera of HIVinfected patients could bind gp120 and neutralize HIV in vitro 69 , early vaccine strategies aimed to induce HIVspecific neutralizing antibodies. Indeed, passive immunization with Envspecific antibodies 70 and early vaccines expressing the HIV Env protein could provide protection in chimpanzees against chal lenge with HIV 12, 13, [16] [17] [18] [19] [71] [72] [73] . However, a lack of efficacy of this strategy was shown in the Phase III clinical trial of VaxGen, a recombinant gp120 envelope protein vaccine that did not induce any protection 20, 21 . These discordant results in chimpanzees and humans might have been due to the small diversity of available HIV challenge viruses that could replicate in chimpanzees, and thus might not be a failure of the model to mimic human HIV infection. However, although chimpanzees are genetically more closely related to humans than are rhesus macaques, chimpanzees that have been experimentally infected with HIV1 to date show low levels of chronic HIV1 replication and generally do not develop any disease or detectable pathology similar to that of HIV1infected humans. Hypotheses that attempt to explain this phen o menon include the absence of chronic immune activation, higher body temperatures in chimpanzees, resistance of monocytes or macrophages to infection with primary HIV isolates, preservation of CD4 + T helper cell regen erative capacity, the absence of HIV1induced auto immune phenomena, the absence of CTl infiltration and the absence of degenerative changes in lymphoid follicles 11, [74] [75] [76] [77] [78] . of note, this lack of disease progression is not a universal phenomenon as a few HIV1infected chimpanzees in captivity have been reported to progress to AIDS and SIVcpz (the chimpanzee strain of SIV)infected chimpanzees in the wild show 10 to 16fold as high mortality [79] [80] [81] . In addition, one viral isolate originating in a chimpanzee with AIDS, HIV1 NC 80, 82 , can induce rapid peripheral CD4 + T cell loss and high levels of virus in the plasma but low virus burden in the peripheral lymph nodes in both previously uninfected and reinfected chimpanzees. So, the protection observed in early chimp anzee studies did not evaluate pathogenic HIV challenge isolates or strains that induce rapid CD4 + T cell depletion, such as HIV1 NC or wildtype SIVcpz.
It should also be noted that manifestation of clinical disease in successful animal models has not always been relevant for effective vaccine development (TABLE 3) ; for example, the chimpanzee hepatitis b virus model did not replicate human disease but still provided the basis for successful development of the human vaccine 83 . However, the failure of the antibodybased vaccine platform in clinical trials and the inability to produce AIDSlike disease in chimpanzees led investigators to consider new nonhuman primate models of HIV and SIV infection that may be of greater relevance to human disease and clinical outcomes.
The next obvious choice of model was rhesus macaques, as they can be experimentally infected by SIV and they develop an AIDSlike disease 84 . However, the use of SIV, not HIV, was of concern (TABLE 4) . because inactivated SIV vaccines that can elicit neutralizing anti bodies failed to protect rhesus macaques from simian AIDS 85 , their relevance was questioned. New recom binant SHIV chimeric viruses were constructed and were observed to be highly pathogenic, causing a rapid, systemic and complete loss of CD4 + T cells in rhesus macaques 86 . Initially, the SHIV system was greeted with excitement and accepted as an important new in vivo challenge model. However, the rapid onset of disease and death in rhesus macaques caused by the highly patho genic nature of this virus was markedly different from that produced by either SIV or HIV, which induce more moderate and gradual loss of CD4 + T cells and slower progression to clinical disease 87 . Despite these concerns, pathogenic SHIV (in particular SHIV89.6p) became a standard challenge model that provided data, which was designated a gatekeeper, for the advancement of HIV vac cines into the clinic. Surprisingly, the highly pathogenic SHIV has proved to be more controllable postchallenge by vaccine regimens that are ineffective at limiting SIV challenge 24, 27, 29, 87 (TABLE 2) . This outcome highlights the troubling possibility that, in rhesus macaques, severity of pathogenesis elicited by the available collection of HIV, 66, 67 and HIV in humans 62, 64, 65 . Whether SIVmac239, SIVmac251 or SIVsmE660 (SIV from sooty mangabeys) is administered in a high dose intravenously or repeated low doses at a mucosal site, peak viral loads occur approximately 1 week earlier in rhesus macaques than for HIV in humans, and the viral loads are on average 2.5-fold greater in magnitude but may be lower following a low-dose inoculation. The establishment of the HIV viral set point in humans that do not receive therapy occurs approximately 14 weeks or more after infection, whereas the SIV viral set point in rhesus macaques is established by week 6. The SIV viral set point is typically in the order of 1 log higher than that of HIV in humans, and simian AIDS-like illness occurs after 0.5-3 years, compared with after 8-10 years in humans.
SHIV and SIV viruses may not correlate with vaccine efficacy in humans, and that pathogenesis is not linked to the establishment of infection, the ultimate goal in vac cine development.
The Merck & Co. HIV vaccine that was tested in the STEP trial used a replicationincompetent Ad5based vector transduced to express HIV proteins. Adenoviruses are nonenveloped, icosahedral viruses that are com posed of a doublestranded linear genome and that infect many avian and mammalian species; more than 50 serotypes of human adenoviruses have been identi fied. because of their efficient nuclear entry mechanism, ability to infect both nondividing and dividing cells, low pathogenicity and robust transgene expression, human adenovirusbased vectors have been widely used for the transduction of various cell types in basic research, in gene therapy applications and in vaccine development 88 . Rhesus macaques were used to develop the Ad5based vaccines, which established the validity of the CTl hypothesis for CTlbased vaccines (that is, that a vac cine inducing HIVspecific CTl responses will protect from disease progression by reducing virus replication) in a primate model. These vaccines were produced in collaboration with and supported by many of the most Human pathogen plus transferrin. CRPV, cottontail rabbit papillomavirus; SIV, simian immunodeficiency virus; SVV, simian varicella virus.
Benchmark
User-defined quantifiable criteria that can be measured using standardized or validated assays. These criteria should be available before advancement into clinical trials to allow for thorough understanding of the defined value of a particular vaccine.
Enzyme-linked immunosorbent spot (ELISPOT) assay
A method based on antibody capture for assessing of the numbers of CD4 + and CD8 + T cells that secrete a particular cytokine (often interferon-γ).
prominent academic laboratories working on primate SIV and SHIV. Results from preclinical studies using the rhesus macaque model of Ad5based vaccination with SHIV challenge supported the advancement of the vaccine into larger clinical trials 22, 25 , despite the vaccine's lack of efficacy against SIVmac239 challenges 26 . In the SHIV89.6p model, vaccination could reduce viral load after acquisition of infection, lower CD4 + T cell loss and decrease or prevent disease progression 22 ; however, as discussed above the vaccine failed to provide protection and possibly enhanced HIV transmission in the STEP clinical trial (TABLE 2) .
Rhesus macaques in HIV and AIDS research
So far we have identified some of the biological and immunological caveats of the rhesus macaque model and learnt that protection against SHIV89.6p and other lowstringency SHIV models is not a good predictor of immunity to HIV in humans. Therefore, the ben efits of using rhesus macaques in further HIV research should be benchmarked. Although protection of rhesus macaques against SHIV89.6p challenge did not predict protection of humans against HIV transmission, lack of protection by Ad5based vaccines in rhesus macaques against SIVmac239 challenge did predict the lack of effi cacy of this approach in humans. Therefore, it would be inappropriate to blame the use of rhesus macaques in those preclinical studies for the failure in clinical trials -only the interpretation of the result showing protec tion in that particular challenge model as a gatekeeper. Perhaps the main implication of the STEP trial is that vaccines that protect rhesus macaques against specific SHIV challenge, but not pathogenic SIV, are unlikely to provide protection against HIV infection in humans. Thus, a lack of evidence supporting the major assump tions regarding protection and nonprotection in rhesus macaques against SIV challenge suggests that the data generated in rhesus macaque challenge models should not be considered a gatekeeper for early clinical advance ment (that is, Phase I clinical trials) until the data can be validated using a predefined immunological correlate in humans
.
Rhesus macaques should be used for hypothesis driven research and the results from immunological screens in these animals can serve as an 'immune gate' for vaccine advancement into Phase I clinical trials. Aside from the known controller MHC haplotypes, in which some individuals spontaneously control the virus 45 , recent evidence in humans suggests that the cytotoxic capac ity of HIVspecific CTls may also correlate with viral control 89 . Therefore, the measurement of interferonγ production by enzyme-linked immunosorbent spot (ELIsPOT) assay and the expression of lysisassociated molecules such as perforin and granzymes by flow cytometry, for example, are quantifiable and can be further examined as immune gates for the advancement of candidate vaccines into human immunogenicity studies. Although some of these criteria are met, in part, by current vaccines studied using nonhuman primates, it remains unclear which effector functions are consistently asso ciated with vaccinemediated control in the absence of controller MHC haplotypes. And, as mentioned earlier, we should attempt to characterize and avoid, or at least stratify, certain MHC haplotypes in rhesus macaques, as the controller Mamu alleles may or may not be representative of immunemediated suppression observed among controller MHC haplotypes in humans (TABLE 1) . Therefore, more standardized and rigorous approaches that are hypothesis driven, quantifiable and defined by desired clinical end points 6 should be used during the preclinical testing of vaccine candidates in rhesus macaques. As such, the rhesus macaque model could be effectively used in safety and immunogenicity studies in which advanced screening strategies and not predetermined gatekeeper status could be applied before consideration for the clinic.
The criteria for determining an immune gate in rhesus macaques for the advancement of candidate vaccines into human immunogenicity studies need to be defined. Clearly, the levels of vaccineinduced immune responses, including memory responses, should be greater than prior preclinically successful vaccine candidates before advancing to the clinic, and so pre vious efficacy trials have established a benchmark for future vaccines. If we consider that currently we have no clinically validated CTlbased approach that is more promising than the use of Ad5 in humans, we know that nextgeneration CTl vaccines must induce 'better' immune responses than Ad5based vaccines do in rhesus macaques. but to establish quantifiable benchmarks to serve as immune gates in this model of vaccination, we need to better define the quality of vaccineinduced immunity in rhesus macaques. The STEP trial was initiated based on only a limited amount of immunogenicity data, aside from protection against SHIV challenge, such as the magnitude and breadth of virusspecific CTl responses as determined by ElISPoT assays. Many questions remain unanswered: what types of T cell memory phenotypes are generated? How polyfunctional are the memory T cells? Do they exhibit proliferative capacity? Do they have a lytic func tion? Do they inhibit virus production by target cells? And how do these quantifiable attributes segregate with the different T cell subsets? Quantifiable immune functions that can be assessed using standard immuno assays should be used to better define benchmarks for the advancement of vaccine candidates from the rhesus macaque model into the clinic. As for a vaccineelicited antibody response, we cur rently have no approach that induces even a modestly broad neutralizing antibody response in humans. The structural features of the HIV Env glycoprotein and its vast variability have frustrated efforts to induce broadly reactive neutralizing antibodies. However, the contri bution of antibodies to protection still remains contro versial. Recent studies show that HIVinfected humans who do generate highly crossreactive, broad neutralizing antibody responses can still become superinfected by a second strain of HIV 90 , suggesting that infection can occur even in the presence of HIVspecific neutralizing antibodies. Furthermore, evidence in rhesus macaques suggests that T cellbased vaccines, when not express ing the Env protein and in the absence of Envspecific antibodies, may have a greater potential than other wise thought in protecting against a challenge with SIVsmE660 (sooty mangabey SIV E660) 91 . Although the role of broadly neutralizing antibodies in protecting against virus transmission remains unclear, they should continue to be an important goal of nextgeneration HIV vaccines -especially because cellfree virus, and not cellassociated virus, was recently reported in a confer ence abstract 92 to be the major source of transmitting virus, suggesting a potentially important role for broadly neutralizing antibodies at mucosal sites. Also, recent studies in rhesus macaques show a correlation between neutralizing antibodies and protection against challenge with a particularly neutralizationsensitive strain of SIV, SIVmac316 (REf. 93) . However, convincing antibody data generated in rabbits and other large animal species, which could include nonhuman primates, showing greater breadth of neutralization must be shown for new antibody approaches to be advanced into Phase I clini cal trials
. Thus, data can be generated in rhesus macaques or other relevant antibodyproducing species without the requirement for protection against SIV or SHIV challenge, which are encouraged for informational purposes to guide future vaccine development.
Box 1 | Rhesus macaques in HIV and AIDS research
The disappointing results from recent clinical trials of candidate HIV vaccines raise questions about the current use of non-human primates and rhesus macaques to generate data used as a 'gatekeeper' for clinical trials.
We think that the data from rhesus macaque virus challenge models should not be considered a gatekeeper for the advancement of a vaccine candidate into clinical trials until it can be validated using a predefined immunological correlate of protection in humans. However, data from challenge studies are useful for informational purposes, hypothesis-driven research and the identification of potential immune targets or goals for the clinic.
Instead, immunological data from the rhesus macaque models could be used as 'immune gates' for the advancement of cytotoxic T lymphocyte (CTL)-and antibody-based vaccines into Phase I clinical trials (see the figure) . CTL-based vaccines should achieve 'better' CTL responses, in terms of the population size, breadth of epitopes targeted, proliferative capacity, cytokine profile and killing activity, than adenovirus serotype 5 (Ad5)-based vaccines in rhesus macaque studies. The immunological data should also be capable of reaching predefined and quantifiable benchmarks of immune responses, such as the induction of CTLs that can kill infected cells at a predefined level and rate. Antibodybased vaccines should elicit 'useful' titres of neutralizing antibodies (according to a defined neutralization end point and response rate) against a panel of HIV envelope (Env)-expressing viruses, not simian immunodeficiency virus (SIV) Env-expressing viruses, in non-human primates, or other antibody-relevant species.
Clinical trials that test CTL vaccine efficacy should proceed only if predefined human immune criteria are met and if these criteria are better than those met by Ad5-based vaccines in humans.
Research is needed to develop better chimeric, HIV Env-expressing SIV viruses, genome-shuffled HIVs and HIV variants to overcome the problems associated with HIV and SIV divergence, neutralization and resistance.
As the recapitulation of human clinical disease in animal models was not relevant for many model systems used for the development of vaccines against other viruses (TABLE 3) , the search for new models using naturally occurring lentiviruses that may or may not mimic HIV disease in humans is important. In light of the STEP trial, the data from rhesus macaque challenge models should not be used as a gatekeeper for Phase I clinical trials, and should be used only for hypothesisdriven basic research until a widely accepted challenge model in rhesus macaques has been validated using a known correlate of protection in humans. A few vaccination strategies have limited the progression to sim ian AIDS in macaques challenged with highly pathogenic SIVmac, such as SIVmac239 and the heterologous swarm viruses SIVmac251 and SIVsmE660 (REf. 94) , which sug gests that their use might provide a more rigorous model for clinical vaccine candidates. However, the current use of various SIV isolates and the techniques in which they are administered to mimic HIV transmission and patho genesis remain controversial. Virus stocks remain too var iable and diverse, and outcomes from the same challenges can differ, the reasons for which are not yet understood. There is little data available to address these issues, most of the data comes from studies of SIV infection in rhe sus macaques that have been carried out by intravenous inoculation with the strains SIVmac239 and SIVmac251 (REf. 5) , which both use CD4 and CCchemokine receptor 5 (CCR5) for entry to host cells [95] [96] [97] and cause acute infections characterized by cellassociated and cellfree viraemia. However, high doses of these viruses are typi cally used to ensure infection, and this practice may overwhelm a potential vaccine response and does not accurately represent the low dose of virus that is associated with natural HIV transmission, which seems to be in the order of one to five transmitted or founder viruses 98, 99 . It is currently thought that experimental transmis sion should replicate natural invasion through the mucosa, using such inoculation techniques as lowdose mucosal challenge 100 . This method of virus delivery to rhesus macaques may be a more useful challenge model for evaluating hypothesisdriven research, as the trans mission of low numbers of founder viruses may better mimic natural transmission in humans. However, it is possible that by using lowdose repeated challenge we are setting the bar too low because in monkeys that are kept in otherwise pathogenfree conditions, and in the absence of cofactors that may influence the acquisi tion of and course of infection, we may see protection that could then disappear in humans harbouring local coinfections. Also, this approach is logistically chal lenging and expensive as more animals are required per group because a productive infection is not always achieved in every animal. but, improvements to mucosal inoculation techniques will undoubtedly enhance their efficacy and utility and may one day include the addition of cofactors such as proinflammatory media tors or microbial coinfection. Thus, lowdose repeated challenge as an administration technique to deliver clini cally relevant isolates of SIV may offer a more physio logically relevant regimen for pathogenic SIV challenge experiments 100 , until an accepted challenge model based on known human correlates can be established.
A greater diversity of challenge isolates in the future may help to better mimic human AIDS in the rhesus macaque model. The SIVsmE660 and SIVmac viruses are currently the challenge viruses of choice, and there are notable differences between these viruses and HIV. For example, their genomes have only a ~55% sequence homology with that of HIV1 whereas they have a ~75% sequence homology with that of HIV2 and a 54-84% sequence homology with SHIVs (fIG. 2) . This moderate level of homology to HIV1 is also observed for the unrelated retrovirus Moloney murine leukaemia retro virus (44% sequence homology). In addition, the rep lication rates, establishment of chronic viral set point and manifestation of AIDS significantly differ between the SIVs and HIV in their respective hosts [101] [102] [103] [104] [105] [106] [107] (fIG. 1) . It is probable that viruses that are generated to have greater homology with HIV and that retain the ability to cause AIDSlike disease could be more useful for rhesus macaque challenge studies than current SIV or SHIV viruses 4 . 
Antiretroviral restriction factors
Host factors, including the TRIM and APOBEC proteins, that function to limit retroviral infection. for example, TRIM5α recognizes motifs in viral capsid proteins and interferes with the uncoating process. APOBEC proteins inhibit retroviruses by deaminating cytosine residues in retroviral cDNA. To counteract this cellular defence, HIV encodes Vif, which mediates APOBEC degradation. Retroviral restriction by these factors is species specific and therefore is a crucial determinant of tropism of retroviral infection.
A better understanding of the key genetic and struc tural differences between the SIV and HIV viruses may help to guide the development of nextgeneration challenge models and/or chimeric virus strains that may better mimic HIV infection and disease pathol ogy in humans. Recombinant simiantropic HIVs have been generated that evade the antiretroviral restriction factors TRIM5α (tripartite motifcontaining 5α) and APobEC3G (apolipoprotein b mRNAediting enzyme, catalytic polypeptidelike 3G) by replacing HIV capsid and Vif sequences with the sequences that effectively evade simian TRIM5α and APobEC3G and this increases the infectivity of the virus in rhesus macaques [108] [109] [110] , but these virus variants have yet to be shown to replicate at high levels and result in HIVlike disease in rhesus macaques. In fact, high levels of virus replication even in the absence of disease may be a valu able vaccine model, as is the case for hepatitis b virus infection of chimpanzees. Also, because SHIVs are more homologous to HIV1 than is SIV, the develop ment of new virus strains that mimic HIV disease but are resistant to treatments that protect against first generation SHIVs may prove useful for vaccine evalu ation 111 . Although attempts to generate more HIVlike SHIVs have failed so far 112, 113 , a better understanding of the interactions between the virus and the host cell may help to identify key viral proteins and/or their specific structural regions that are required for replication of HIV in nonhuman primates. Such a development may help the challenge model to better resemble those pre clinical rhesus macaque models that successfully used a human pathogen for vaccine studies and licensure (TABLE 3) ; out of the 24 vaccines currently licensed in the United States, ~40% were successfully developed using nonhuman primates but only 11% of those effectively used a simian virus instead of the human pathogen as a model. Therefore, we should certainly not dismiss the use of current rhesus macaque challenge models for vac cine research. It is important that new hypotheses based on the outcome of challenge studies are generated, as these can drive the development and clinical testing based on new benchmarks.
In summary, Phase I clinical trials of candidate HIV vaccines evaluating safety and predefined immune cor relates are crucial for the advancement of HIV studies but should not be continued to efficacy trials unless the vac cine's immunogenicity is shown to be better than that of Ad5based vaccines in humans. This is a crucial goal for HIV vaccine development that should be considered inde pendently from SIV and SHIV challenge models owing to the fact there is limited evidence that protection in rhe sus macaques equates to protection in humans
. So, approaches that are advanced to clinical trials must produce better immune responses in rhesus macaques in standardized and quantifiable immunogenicity experi ments than approaches tested in clinical trials so far. Nevertheless, to study vaccine candidates in the clinical setting, it is still useful to examine them in current SIV challenge models, as the information generated from these studies can guide future vaccine development.
Concluding remarks
The road to an HIV vaccine using the nonhuman primate model has been turbulent and controversial and has met with far fewer instances of success than failure. both of the two human HIV vaccine efficacy trials conducted to date have failed. but we must not let this stop us from moving forward. Despite the many limiting factors surrounding the use of nonhuman primates in preclinical research, rhesus macaques have made countless contributions to the understanding, treatment and prevention of human disease (TABLE 3) . we must proceed in the fight against HIV and AIDS using the best animal model possible in a responsible, hypothesisdriven and ethical manner. Data from the rhesus macaque model must be critically evaluated to maximize the rational design of HIV vaccines and to ensure their safety and immunogenicity when moved into clinical trials. Advanced screening strategies using predefined immune gates in preclinical studies should be designed to eliminate suboptimal vaccine candidates early in the testing process. before clinical trial advance ment there should be immune response data in non human primates 6 
. An HIV vaccine approach that moves forward in the clinic should continue to be stud ied in validated macaque models in which information on outcomes, as well as further definition of immune phenotype, is obtained. Gatekeeper status cannot be assigned to a particular challenge model until a known correlate in humans is defined. However, primate stud ies can function as immune gates to identify new vac cines and to define new immune gates that show a level of improvement over prior nonsuccessful vaccine can didates for clinical evaluation. Thus, we need to remain cautious when using animal models in experimentation, critical during the interpretation of data and vigilant in our quest to apply such information to the prevention of human disease. This in mind, we would be wise to heed the words of statistician George E. P. box: "all models are wrong, but some are useful" 114 .
